Tel: 01223 330307
Simon Griffin is Professor of General Practice at the University of Cambridge, Group Leader in the Medical Research Council Epidemiology Unit (www.mrc-epid.cam.ac.uk) and CEDAR (the UKCRC Public Health Centre of Excellence for Diet and Activity Research, http://www.cedar.iph.cam.ac.uk/), Honorary Professor of General Medical Practice at Aarhus University Denmark, Honorary Consultant at Cambridge University Hospitals NHS Foundation Trust, assistant General Practitioner at Lensfield Medical Practice (http://www.lensfieldpractice.org/), NIHR Senior Investigator (https://www.nihr.ac.uk/our-faculty/senior-investigators/) and Fellow of the Academy of Medical Sciences (https://acmedsci.ac.uk/), the Royal College of General Practitioners (http://www.rcgp.org.uk/) and Wolfson College (http://www.wolfson.cam.ac.uk/). He qualified from the London Hospital Medical College in 1986 and trained in Clinical Epidemiology and Public Health at the University of Southampton and the London School of Hygiene and Tropical Medicine prior to his appointment to the University of Cambridge in 1998. In 2005 Simon joined the MRC Epidemiology Unit as Assistant Director and was appointed Professor of General Practice in May 2013. Away from work Simon plays soccer and surfs.
Simon leads a research programme which contributes to efforts aimed at preventing the growing burden of non-communicable disease including obesity, diabetes, cardiovascular disease and cancer, by translating epidemiological knowledge into preventive action, and evaluating the effectiveness of a range of preventive approaches in randomised trials. He published the first diabetes risk score and the first trial of screening for type 2 diabetes. He has completed over 30 trials and authored over 350 publications
Godino JG, van Sluijs EMF, Marteau TM, Sutton S, Sharp SJ, Griffin SJ. Lifestyle advice combined with personalized estimate of genetic or phenotypic risk of type 2 diabetes, and objectively measured physical activity: a randomized controlled trial. PLoS Med 2016;13(11):e1002185.
Usher-Smith JA, Sharp SJ, Griffin SJ. The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 2016;353:i3139.
Burgoine T, Forouhi N, Griffin S, Wareham N, Monsivais P. Associations between exposure to takeaway food outlets, takeaway food consumption, and body weight in Cambridgeshire, UK: population based, cross sectional study. BMJ 2014;348:g1464.
Simmons R, Echouffo-Tcheugui J, Sharp S, Sargeant L, Williams K, Prevost T. Kinmonth A, Wareham N, Griffin SJ. Screening for type 2 diabetes on population mortality over ten years: the ADDITION-Cambridge cluster-randomised controlled trial. Lancet 2012; 380: 1741-8.
Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-167.
Chamnan P, Simmons RK, Khaw K-T, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ 2010;340:c1693.
Paddison CAM, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth AL, Griffin SJ. Are people with negative screening tests falsely reassured? A parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009;339:b4535.
Kinmonth A-L, Wareham NJ, Hardeman W, Sutton S, Prevost AT, Fanshawe T, Williams KM, Ekelund U, Spiegelhalter D, Griffin SJ. Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. Lancet 2008;371:41-48.
van Sluijs EMF, McMinn A, Griffin SJ. Effectiveness of interventions to promote physical activity in children and adolescents: systematic review of controlled trials. BMJ 2007;335:703-707.
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, van Hoek M, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Boström KB, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, Chines PS, Cornelis M, Couper DJ, Crawford G, Doney ASF, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PRV, Jørgensen T, Kao WHL, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JRB, Petersen A-K, Platou C, Proença C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparsø T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, The MAGIC investigators, The GIANT consortium, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CAN, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann H-E, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579–589.
For a full list of publications, please see Simon’s pages on Google Scholar